Search Results

mispronunciations, cultural differences, and the importance of a multidisciplinary approach in drug development discussed their research interests, particularly in the field of GPCR, and the importance of method development discussed their professional backgrounds, highlighting the benefits of a multidisciplinary approach in drug development They also highlighted the importance of method development, integrity, and honesty in scientific research

Department, Ken Vecchio helping set the foundation for the Nanoengineering Materials Research Center and developing Scientists and Engineers working at the nanoscale, specifically protein engineering and small molecule drug development

This was followed by a postdoctoral role at the Polytechnic University of Turin (Italy), where he developed Now in a tenure-track position, his research spans the development of computational methods such as structure-based

Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development I have participated and initiated methodologies for development of pharmacologically active anti-GPCR

My project involved the development of FRET/BRET -based GPCR conformational biosensors, which can be I spent 2 1/2 years in his lab and developed novel conformational sensors for these intriguing receptors

identification of small molecule regulators of these proteins, and progressing such ligands in drug development non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing

Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development within the primary cilium, a tiny antenna-shaped structure at the cell surface with critical links to development Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford

academia, she co-founded two GPCR-focused biotechs with Heidi Hamm - CUE Biotech and Caden Biosciences - developing as a discipline shaped how she has thought about the relationship between target validation and drug development The peptides she developed - 11 amino acids rather than 55, which created their own detection challenges argument Biologics have a substantially higher success rate than small molecules moving through the drug development therapeutics an underexplored area - particularly for orphan GPCRs, where compounds are already being developed

Together with Irina Kufareva , UCSD, her team developed a novel approach to identifying ligands for orphan GPCRs by developing a powerful new computational tool for identifying ‘surrogate’ ligands (borrowed

Mid-career, he has worked in finance and developed high-frequency trading systems. early-stage medical device start-up and in 5 years was responsible for project R&D and managing a focused development

His lab develops BRET- and FRET-based biosensors that produce different conformational outputs depending His research centers on GPCR signaling networks, biosensor development, and the role of cellular context His lab develops resonance energy transfer-based biosensors and applies them in induced pluripotent stem Hebert's lab developed caged ligands that cross the plasma membrane and are uncaged intracellularly,

They also explored the possibility of developing an ecosystem for the GPCR University. Developing a Research Ecosystem at GPCR University Yamina and Claudia discussed developing an ecosystem

and experimental systems (purified proteins, cultured cells, model organisms) in combination with the development Our ongoing efforts have direct implications in cancer, embryonic development defects, and neurological

Pivoting: Redefining the Pain Research Playbook Looking ahead, Serafini’s vision is bold: build a lab that develops He aspires to become a physician-scientist, with a focus on translational in vitro and in vivo model development Other academic interests of his include studying pharmaceutical finance & healthcare administration and developing

Yekkirala shares the pivotal moments that transformed him from a curious PhD student into a GPCR drug developer scientists interested in translational innovation Biotech investors and strategic leaders seeking new drug development

In this conversation, Charlotte Crauwels discusses her work developing computational strategies to support Her research centers on developing computational pipelines that guide the design of hybrid or chimeric Eventually, I connected with my current supervisor and began developing GPCR-related research projects Charlotte Crauwels: The goal of my PhD was to develop a computational pipeline that supports the design

His work developed the thermostabilization platform - a systematic approach to engineering receptor stability In 2005 he started working on the development of conformational thermostabilization of GPCRs, which resulted In 2016 mini-G proteins were developed as a tool for the structure determination of GPCRs in the fully

with receptors such as the μ-opioid and κ-opioid receptors, and how structural insights can guide the development interface of structural biology and drug discovery, where molecular structures inform the design and development One direction is to develop new tools using well-characterized receptors—the ones we understand well I can imagine myself in a biotech or pharmaceutical environment where I’m helping guide drug development Essentially serving as a bridge between the science and the development process. Dr.

SCIENTIFIC THEMES OF THE CONVERSATION The GPCR antibody reliability problem - how it developed, why it systematic characterization requires Immunogen selection as the critical upstream decision in GPCR antibody development crypts and implicated in several malignancies - was the target that made the difficulty of GPCR antibody development

He has more than 20 years of experience in GPCR, primarily focused on drug discovery and developing new

properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic development

Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development

His work focuses on developing novel β₂-adrenergic ligands that selectively engage signaling pathways entrepreneur and founder of biotechnology companies translating GPCR pharmacology into therapeutic development Another company, Atrogi, is based on our research on β₂-adrenergic receptors and the development of new

His lab focuses on developing and innovating technologies to solve broad questions in pharmacology, with

We have developed an array of fluorescent biosensors to map kinase activity in living cells and are exploring

(MFI): a reliable, self-sustaining computational chemistry service provider, developing its own software

Alice Ting developing programmable receptors for molecular sensing and controlling cellular behaviour

She developed expertise over the past two decades studying structure/function relationships of GPCRs

Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors

She is an internationally recognized biophysicist for her contributions in developing constrained molecular